{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:25:14Z","timestamp":1782451514238,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,8,28]],"date-time":"2009-08-28T00:00:00Z","timestamp":1251417600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Drug-resistant tuberculosis (DR-TB) is considered a real threat to the achievement of TB control. Testing of mycobacterial culture and testing of drug susceptibility (DST) capacity are limited in resource-poor countries, therefore inadequate treatment may occur, favouring resistance development. We evaluated the molecular assay GenoType<jats:sup>\u00ae<\/jats:sup> MTBDR<jats:italic>plus<\/jats:italic> (Hain Lifescience, Germany) in order to detect DR-TB directly in clinical specimens as a means of providing a more accurate management of chronic TB patients in Burkina Faso, a country with a high TB-HIV co-infection prevalence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Samples were collected in Burkina Faso where culture and DST are not currently available, and where chronic cases are therefore classified and treated based on clinical evaluation and sputum-smear microscopy results. One hundred and eight chronic TB patients (sputum smear-positive, after completing a re-treatment regimen for pulmonary TB under directly observed therapy) were enrolled in the study from December 2006 to October 2008. Two early morning sputum samples were collected from each patient, immediately frozen, and shipped to Italy in dry ice. Samples were decontaminated, processed for smear microscopy and DNA extraction. Culture was attempted on MGIT960 (Becton Dickinson, Cockeysville, USA) and decontaminated specimens were analyzed for the presence of mutations conferring resistance to rifampin and isoniazid by the molecular assay GenoType<jats:sup>\u00ae<\/jats:sup> MTBDR<jats:italic>plus<\/jats:italic>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We obtained a valid molecular test result in 60\/61 smear-positive and 47\/47 smear-negative patients.<\/jats:p>\n            <jats:p>Among 108 chronic TB cases we identified patients who (i) harboured rifampin- and isoniazid-susceptible strains (n 24), (ii) were negative for MTB complex DNA (n 24), and (iii) had non-tuberculous mycobacteria infections (n 13). The most represented mutation conferring rifampin-resistance was the D516V substitution in the hotspot region of the <jats:italic>rpoB<\/jats:italic> gene (43.8% of cases). Other mutations recognized were the H526D (15.6%), the H526Y (15.6%), and the S531L (9.4%).<\/jats:p>\n            <jats:p>All isoniazid-resistant cases (n 36) identified by the molecular assay were carrying a S315T substitution in the <jats:italic>katG<\/jats:italic> gene. In 41.7% of cases, a mutation affecting the promoter region of the <jats:italic>inhA<\/jats:italic> gene was also detected.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The GenoType<jats:sup>\u00ae<\/jats:sup> MTBDR<jats:italic>plus<\/jats:italic> assay performed directly on sputum specimens improves the management of chronic TB cases allowing more appropriate anti-TB regimens.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2334-9-142","type":"journal-article","created":{"date-parts":[[2009,8,28]],"date-time":"2009-08-28T18:14:11Z","timestamp":1251483251000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso"],"prefix":"10.1186","volume":"9","author":[{"given":"Paolo","family":"Miotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuccia","family":"Saleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathurin","family":"Dembel\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martial","family":"Ouedraogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gis\u00e8le","family":"Badoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Pinsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni B","family":"Migliori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Matteelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela M","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,28]]},"reference":[{"key":"907_CR1","volume-title":"WHO Report 2007. Global tuberculosis control. Surveillance, planning, financing","author":"World Health Organization","year":"2007","unstructured":"World Health Organization: WHO Report 2007. Global tuberculosis control. Surveillance, planning, financing. 2007, WHO; Geneva"},{"key":"907_CR2","volume-title":"The global MDR-TB and XDR-TB response plan, 2007\u20132008","author":"World Health Organization","year":"2007","unstructured":"World Health Organization: The global MDR-TB and XDR-TB response plan, 2007\u20132008. 2007, WHO; Geneva"},{"key":"907_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1086\/505877","volume":"194","author":"M Zignol","year":"2006","unstructured":"Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, Williams BG, Dye C: Global incidence of multidrug-resistant tuberculosis. J Infect Dis. 2006, 194: 479-485. 10.1086\/505877.","journal-title":"J Infect Dis"},{"key":"907_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/07853890310005713","volume":"35","author":"PD Davies","year":"2003","unstructured":"Davies PD: The world-wide increase in tuberculosis: how demographic changes, HIV infection and increasing numbers in poverty are increasing tuberculosis. Ann Med. 2003, 35: 235-243. 10.1080\/07853890310005713.","journal-title":"Ann Med"},{"key":"907_CR5","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(06)69573-1","volume":"368","author":"NR Gandhi","year":"2006","unstructured":"Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G: Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006, 368: 1575-1580. 10.1016\/S0140-6736(06)69573-1.","journal-title":"Lancet"},{"key":"907_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/09031936.00168008","volume":"33","author":"G Sotgiu","year":"2009","unstructured":"Sotgiu G, Ferrara G, Matteelli A, Richardson MD, Centis R, Ruesch-Gerdes S, Toungoussova O, Zellweger J-P, Spanavello A, Cirillo D, Lange C, Migliori GB: Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J. 2009, 33: 1-10.1183\/09031936.00168008.","journal-title":"Eur Respir J"},{"key":"907_CR7","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1128\/JCM.41.3.1235-1239.2003","volume":"41","author":"K Adjers-Koskela","year":"2003","unstructured":"Adjers-Koskela K, Katila ML: Susceptibility testing with the manual mycobacteria growth indicator tube (MGIT) and the MGIT 960 system provides rapid and reliable verification of multidrug-resistant tuberculosis. J Clin Microbiol. 2003, 41: 1235-1239. 10.1128\/JCM.41.3.1235-1239.2003.","journal-title":"J Clin Microbiol"},{"key":"907_CR8","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1046\/j.1469-0691.2003.00783.x","volume":"9","author":"KA Angeby","year":"2003","unstructured":"Angeby KA, Werngren J, Toro JC, Hedstrom G, Petrini B, Hoffner SE: Evaluation of the BacT\/ALERT 3D system for recovery and drug susceptibility testing of Mycobacteriumtuberculosis. Clin Microbiol Infect. 2003, 9: 1148-1152. 10.1046\/j.1469-0691.2003.00783.x.","journal-title":"Clin Microbiol Infect"},{"key":"907_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1128\/JCM.44.1.20-28.2006","volume":"44","author":"C Piersimoni","year":"2006","unstructured":"Piersimoni C, Olivieri A, Benacchio L, Scarparo C: Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems. J Clin Microbiol. 2006, 44: 20-28. 10.1128\/JCM.44.1.20-28.2006.","journal-title":"J Clin Microbiol"},{"key":"907_CR10","volume-title":"Global plan to stop TB 2006\u20132015","author":"World Health Organization, StopTB Partnership","year":"2006","unstructured":"World Health Organization, StopTB Partnership: Global plan to stop TB 2006\u20132015. 2006, WHO; Geneva"},{"key":"907_CR11","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S0140-6736(06)68392-X","volume":"367","author":"MC Raviglione","year":"2006","unstructured":"Raviglione MC, Uplekar MW: WHO's new Stop TB Strategy. Lancet. 2006, 367: 952-955. 10.1016\/S0140-6736(06)68392-X.","journal-title":"Lancet"},{"key":"907_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1183\/09031936.00001307","volume":"29","author":"GB Migliori","year":"2007","unstructured":"Migliori GB, Loddenkemper R, Blasi F, Raviglione MC: 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is \"science\" enough to tackle the epidemic?. Eur Respir J. 2007, 29: 423-427. 10.1183\/09031936.00001307.","journal-title":"Eur Respir J"},{"key":"907_CR13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1155\/2008\/857901","volume":"19","author":"GB Migliori","year":"2008","unstructured":"Migliori GB, Matteelli A, Cirillo D, Pai M: Diagnosis ofmultidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current standards and challenges. Can J Infect Dis Med Microbiol. 2008, 19: 169-172.","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"907_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1586\/14737159.6.3.423","volume":"6","author":"M Pai","year":"2006","unstructured":"Pai M, Kalantri S, Dheda K: New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. Expert Rev Mol Diagn. 2006, 6: 423-432. 10.1586\/14737159.6.3.423.","journal-title":"Expert Rev Mol Diagn"},{"issue":"Suppl 1","key":"907_CR15","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1086\/518656","volume":"196","author":"MD Perkins","year":"2007","unstructured":"Perkins MD, Cunningham J: Facing the crisis: improvingthe diagnosis of tuberculosis in the HIV era. J Infect Dis. 2007, 196 (Suppl 1): S15-27. 10.1086\/518656.","journal-title":"J Infect Dis"},{"key":"907_CR16","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1183\/09031936.06.00084906","volume":"28","author":"FA Drobniewski","year":"2006","unstructured":"Drobniewski FA, Hoffner S, Rusch-Gerdes S, Skenders G, Thomsen V: Recommended standards for modern tuberculosis laboratory services in Europe. Eur Respir J. 2006, 28: 903-909. 10.1183\/09031936.06.00084906.","journal-title":"Eur Respir J"},{"key":"907_CR17","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1164\/rccm.200709-1436OC","volume":"177","author":"M Barnard","year":"2008","unstructured":"Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME: Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med. 2008, 177: 787-792. 10.1164\/rccm.200709-1436OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"907_CR18","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1128\/JCM.00521-07","volume":"45","author":"D Hillemann","year":"2007","unstructured":"Hillemann D, Rusch-Gerdes S, Richter E: Evaluation ofthe GenoType\u00ae MTBDR plus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol. 2007, 45: 2635-2640. 10.1128\/JCM.00521-07.","journal-title":"J Clin Microbiol"},{"key":"907_CR19","volume-title":"Global Tuberculosis Control 2008. Surveillance, Planning, Financing","author":"World Health Organization","year":"2008","unstructured":"World Health Organization: Global Tuberculosis Control 2008. Surveillance, Planning, Financing. 2008, WHO; Geneva"},{"key":"907_CR20","volume-title":"Report on the HIV\/AIDS epidemic 2008","author":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)","year":"2008","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS): Report on the HIV\/AIDS epidemic 2008. 2008, WHO; Geneva"},{"key":"907_CR21","volume-title":"Plan d'action 2009 du Programme National Tuberculose. Ouagadougou, Burkina Faso","author":"National Tuberculosis Program, Ministry of Health Burkina Faso","year":"2009","unstructured":"National Tuberculosis Program, Ministry of Health Burkina Faso: Plan d'action 2009 du Programme National Tuberculose. Ouagadougou, Burkina Faso. 2009, 10.1183\/09031936.00061808."},{"key":"907_CR22","volume-title":"Implementing the WHO Stop TBstrategy. A handbook for national tuberculosis control programmes","author":"World Health Organization","year":"2008","unstructured":"World Health Organization: Implementing the WHO Stop TBstrategy. A handbook for national tuberculosis control programmes. 2008, WHO; Geneva"},{"key":"907_CR23","volume-title":"Guidelines for theprogrammatic management of drug resistant tuberculosis \u2013 emergency update 2008","author":"World Health Organization","year":"2008","unstructured":"World Health Organization: Guidelines for theprogrammatic management of drug resistant tuberculosis \u2013 emergency update 2008. 2008, WHO; Geneva"},{"key":"907_CR24","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1183\/09031936.00061808","volume":"32","author":"DI Ling","year":"2008","unstructured":"Ling DI, Zwerling AA, Pai M: GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J. 2008, 32: 1165-1174. 10.1054\/tuld.1998.0002.","journal-title":"Eur Respir J"},{"key":"907_CR25","volume-title":"Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement","author":"World Health Organization","year":"2008","unstructured":"World Health Organization: Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement. 2008, WHO; Geneva"},{"key":"907_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1054\/tuld.1998.0002","volume":"79","author":"S Ramaswamy","year":"1998","unstructured":"Ramaswamy S, Musser JM: Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 1998, 79: 3-29. 10.1054\/tuld.1998.0002.","journal-title":"Tuber Lung Dis"},{"key":"907_CR27","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1128\/AAC.40.11.2655","volume":"40","author":"SL Moghazeh","year":"1996","unstructured":"Moghazeh SL, Pan X, Arain T, Stover CK, Musser JM, Kreiswirth BN: Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother. 1996, 40: 2655-2657.","journal-title":"Antimicrob Agents Chemother"},{"key":"907_CR28","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1054\/drup.2001.0196","volume":"40","author":"H Ohno","year":"1996","unstructured":"Ohno H, Koga H, Kohno S, Tashiro T, Hara K: Relationshipbetween rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother. 1996, 40: 1053-1056. 10.1054\/drup.2001.0196.","journal-title":"Antimicrob Agents Chemother"},{"key":"907_CR29","volume-title":"Laboratory Services in Tuberculosis Control \u2013 Culture Part III","author":"World Health Organization","year":"1998","unstructured":"World Health Organization: Laboratory Services in Tuberculosis Control \u2013 Culture Part III. 1998, WHO; Geneva"},{"key":"907_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1054\/drup.2001.0196","volume":"4","author":"F Baquero","year":"2001","unstructured":"Baquero F: Low-level antibacterial resistance: a gateway to clinical resistance. Drug Resist Updat. 2001, 4: 93-105. 10.1054\/drup.2001.0196.","journal-title":"Drug Resist Updat"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-9-142\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T08:16:27Z","timestamp":1630484187000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-9-142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,28]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["907"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-9-142","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,28]]},"assertion":[{"value":"13 March 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"142"}}